Ravenstone Capital Management’s Johnson & Johnson JNJ Stock Holding History

Ravenstone Capital Management’s Portfolio JNJ Stock Details JNJ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-21	Closed	-$3.48K	–	68
2025 Q1	$3.48K	Buy	+21	New	+$3.29K	﹤0.01%	72
2021 Q4	–	Sell	-47	Closed	-$7.59K	–	78
2021 Q3	$7.59K	Buy	+47	New	+$8.02K	0.01%	55

Other funds holding JNJ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ravenstone Capital Management's JNJ Position: Q2 2025 in Review

Ravenstone Capital Management sold out of Johnson & Johnson (JNJ) in Q2 2025, closing a stake of 21 shares — an estimated $3.48K sold.

Ravenstone Capital Management first reported a position in JNJ in Q3 2021 and held it in 2 quarters. The position peaked at $7.59K in Q3 2021. 4,083 funds tracked by Wall St. Rank hold JNJ as of Q2 2025.

Ravenstone Capital Management reported no remaining Johnson & Johnson position as of Q2 2025 after selling out during the quarter.
Ravenstone Capital Management sold 21 Johnson & Johnson shares in Q2 2025, an estimated $3.48K.
Ravenstone Capital Management first reported a position in Johnson & Johnson in Q3 2021 and held it in 2 quarters.
Ravenstone Capital Management's Johnson & Johnson position peaked at $7.59K in Q3 2021.
4,083 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2025.

Based on Ravenstone Capital Management's 13F filing for Q2 2025, filed 26 Jun 2026.